Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

Bastiaan De Galan, Sophia Zoungas, John Chalmers, Craig Anderson, Carole Dufouil, A Pillai, Mark Cooper, Diederick Grobbee, Maree Hackett, Pavel Hamet, S Heller, Lisheng Liu, Stephen MacMahon, Giuseppe Mancia, Bruce Neal, Chang Yu Pan, Anushka Patel, Neil Poulter, Florence Travert, Mark Woodward

    Research output: Contribution to journalArticle

    139 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)2328-2336
    Number of pages9
    JournalDiabetologia
    Volume52
    Issue number11
    Publication statusPublished - 2009

    Cite this

    De Galan, B., Zoungas, S., Chalmers, J., Anderson, C., Dufouil, C., Pillai, A., Cooper, M., Grobbee, D., Hackett, M., Hamet, P., Heller, S., Liu, L., MacMahon, S., Mancia, G., Neal, B., Pan, C. Y., Patel, A., Poulter, N., Travert, F., & Woodward, M. (2009). Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia, 52(11), 2328-2336.